NORPLANT®: Levonorgestrel-releasing contraceptive implant

Resultado de la investigación: Article

24 Citas (Scopus)

Resumen

NORPLANT® is the newest contraceptive system to be introduced world-wide, with nearly a million current users. It consists of six Silastic capsules containing levonorgestrel (LNg), which are inserted under the skin in the arm. Release of the steroid commences immediately so that, after several weeks, circulating levels of LNg stabilize between 0.3 and 0.4 ng/ml of plasma, and they persist elevated with a minor decline for over 5 years. The gross cumulative pregnancy rate at 5 years is 2.6 per 100 woman-years. In the majority of women it produces no abnormalities in a variety of clinical chemistry, metabolic, haematological and coagulation parameters. The most common side-effect is disruption of the menstrual bleeding pattern; this is reported by two-thirds of the users in the first months and by one-third by the fifth year. Because it is the most disturbing side-effect for many users, counselling prior to insertion is of paramount Importance. NORPLANT® exerts varying degrees of gonadotropin and ovarian inhibition, including anovulation and luteal insufficiency. Endometrial development is irregular and, Irrespective of oestrogen levels, cervical mucus is thick and scanty at all times due to the strong antioestrogenic effect of LNg. Inhibition of sperm penetration fully accounts for the antifertility effect of NORPLANT® in ovulatory cycles. The high contraceptive efficacy, lack of serious side-effects, reversibility and the convenience of long-term unattended use explain the high acceptability of NORPLANT®.

Idioma originalEnglish
Páginas (desde-hasta)155-160
Número de páginas6
PublicaciónAnnals of Medicine
Volumen25
N.º2
DOI
EstadoPublished - 1 ene 1993

Huella dactilar

Levonorgestrel
Contraceptive Agents
Anovulation
Sperm-Ovum Interactions
Cervix Mucus
Clinical Chemistry
Corpus Luteum
Pregnancy Rate
Gonadotropins
Capsules
Counseling
Estrogens
Steroids
Hemorrhage
Skin
Inhibition (Psychology)

ASJC Scopus subject areas

  • Medicine(all)

Citar esto

@article{037560fa924640b3ad78956477289fb8,
title = "NORPLANT{\circledR}: Levonorgestrel-releasing contraceptive implant",
abstract = "NORPLANT{\circledR} is the newest contraceptive system to be introduced world-wide, with nearly a million current users. It consists of six Silastic capsules containing levonorgestrel (LNg), which are inserted under the skin in the arm. Release of the steroid commences immediately so that, after several weeks, circulating levels of LNg stabilize between 0.3 and 0.4 ng/ml of plasma, and they persist elevated with a minor decline for over 5 years. The gross cumulative pregnancy rate at 5 years is 2.6 per 100 woman-years. In the majority of women it produces no abnormalities in a variety of clinical chemistry, metabolic, haematological and coagulation parameters. The most common side-effect is disruption of the menstrual bleeding pattern; this is reported by two-thirds of the users in the first months and by one-third by the fifth year. Because it is the most disturbing side-effect for many users, counselling prior to insertion is of paramount Importance. NORPLANT{\circledR} exerts varying degrees of gonadotropin and ovarian inhibition, including anovulation and luteal insufficiency. Endometrial development is irregular and, Irrespective of oestrogen levels, cervical mucus is thick and scanty at all times due to the strong antioestrogenic effect of LNg. Inhibition of sperm penetration fully accounts for the antifertility effect of NORPLANT{\circledR} in ovulatory cycles. The high contraceptive efficacy, lack of serious side-effects, reversibility and the convenience of long-term unattended use explain the high acceptability of NORPLANT{\circledR}.",
keywords = "Contraception, Implant, Levonorgestrel, NORPLANT, Silastic",
author = "Croxatto, {Horacio B.}",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/07853899309164160",
language = "English",
volume = "25",
pages = "155--160",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "2",

}

NORPLANT® : Levonorgestrel-releasing contraceptive implant. / Croxatto, Horacio B.

En: Annals of Medicine, Vol. 25, N.º 2, 01.01.1993, p. 155-160.

Resultado de la investigación: Article

TY - JOUR

T1 - NORPLANT®

T2 - Levonorgestrel-releasing contraceptive implant

AU - Croxatto, Horacio B.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - NORPLANT® is the newest contraceptive system to be introduced world-wide, with nearly a million current users. It consists of six Silastic capsules containing levonorgestrel (LNg), which are inserted under the skin in the arm. Release of the steroid commences immediately so that, after several weeks, circulating levels of LNg stabilize between 0.3 and 0.4 ng/ml of plasma, and they persist elevated with a minor decline for over 5 years. The gross cumulative pregnancy rate at 5 years is 2.6 per 100 woman-years. In the majority of women it produces no abnormalities in a variety of clinical chemistry, metabolic, haematological and coagulation parameters. The most common side-effect is disruption of the menstrual bleeding pattern; this is reported by two-thirds of the users in the first months and by one-third by the fifth year. Because it is the most disturbing side-effect for many users, counselling prior to insertion is of paramount Importance. NORPLANT® exerts varying degrees of gonadotropin and ovarian inhibition, including anovulation and luteal insufficiency. Endometrial development is irregular and, Irrespective of oestrogen levels, cervical mucus is thick and scanty at all times due to the strong antioestrogenic effect of LNg. Inhibition of sperm penetration fully accounts for the antifertility effect of NORPLANT® in ovulatory cycles. The high contraceptive efficacy, lack of serious side-effects, reversibility and the convenience of long-term unattended use explain the high acceptability of NORPLANT®.

AB - NORPLANT® is the newest contraceptive system to be introduced world-wide, with nearly a million current users. It consists of six Silastic capsules containing levonorgestrel (LNg), which are inserted under the skin in the arm. Release of the steroid commences immediately so that, after several weeks, circulating levels of LNg stabilize between 0.3 and 0.4 ng/ml of plasma, and they persist elevated with a minor decline for over 5 years. The gross cumulative pregnancy rate at 5 years is 2.6 per 100 woman-years. In the majority of women it produces no abnormalities in a variety of clinical chemistry, metabolic, haematological and coagulation parameters. The most common side-effect is disruption of the menstrual bleeding pattern; this is reported by two-thirds of the users in the first months and by one-third by the fifth year. Because it is the most disturbing side-effect for many users, counselling prior to insertion is of paramount Importance. NORPLANT® exerts varying degrees of gonadotropin and ovarian inhibition, including anovulation and luteal insufficiency. Endometrial development is irregular and, Irrespective of oestrogen levels, cervical mucus is thick and scanty at all times due to the strong antioestrogenic effect of LNg. Inhibition of sperm penetration fully accounts for the antifertility effect of NORPLANT® in ovulatory cycles. The high contraceptive efficacy, lack of serious side-effects, reversibility and the convenience of long-term unattended use explain the high acceptability of NORPLANT®.

KW - Contraception

KW - Implant

KW - Levonorgestrel

KW - NORPLANT

KW - Silastic

UR - http://www.scopus.com/inward/record.url?scp=0027336361&partnerID=8YFLogxK

U2 - 10.3109/07853899309164160

DO - 10.3109/07853899309164160

M3 - Article

C2 - 8489753

AN - SCOPUS:0027336361

VL - 25

SP - 155

EP - 160

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 2

ER -